Summit Therapeutics Announces Placement of £15.0 Million of Ordinary Shares
Mar 27, 2018 11:01 am UTC| Business
OXFORD, United Kingdom, March 27, 2018 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection,...
FactSet Reports Strong Revenue Growth in Second Quarter 2018
Mar 27, 2018 11:01 am UTC| Business
NORWALK, Conn., March 27, 2018 -- FactSet (the “Company”) (NYSE:FDS) (NASDAQ:FDS), a global provider of integrated financial information, analytical applications, and industry-leading service, today announced its...
iAnthus Applauds U.S. Congress Reauthorizing the Rohrabacher-Blumenauer Amendment
Mar 27, 2018 11:01 am UTC| Business
NEW YORK and TORONTO, March 27, 2018 -- iAnthus Capital Holdings, Inc. (“iAnthus” or “the Company”), (CSE:IAN) (OTCQB:ITHUF), which owns, operates, and partners with licensed cannabis operations throughout the United...
True Leaf Announces Appointment of Chief Scientific Officer and Medical Advisory Board
Mar 27, 2018 11:01 am UTC| Business
VERNON, British Columbia, March 27, 2018 -- True Leaf Medicine International Ltd. (“True Leaf”) (CSE:MJ) (FSE:TLA) (OTCQB:TRLFF), the quality of life cannabis company for people and their pets, announced today the...
Mar 27, 2018 11:01 am UTC| Business
NEW YORK, March 27, 2018 -- Extenua CEO, Steve Visconti, told us, “The recent ransomware attack on the city of Atlanta (https://www.cnn.com/2018/03/22/us/atlanta-ransomware-attack/index.html) is an ominous development....
Eli Electric Vehicles Offers Exclusive Pricing for Eli ZERO Pre-Order Customers
Mar 27, 2018 11:01 am UTC| Business
LONG BEACH, Calif., March 27, 2018 -- Eli Electric Vehicles, creating the next generation of Neighborhood Electric Vehicles (NEV), today announced exclusive pricing for early adopter customers who reserve an Eli ZERO, a...
miRagen Announces Initiation of Phase 1 Clinical Trial of MRG-110
Mar 27, 2018 11:00 am UTC| Business
BOULDER, Colo., March 27, 2018 -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today the initiation...